Bostal LLC
June 16, 2025
Company Presentation
Brain Health
Bostal LLC is an enabling platform technology pharmaceutical company. Established in New Jersey in 2004, Bostal expanded its global footprint, Bostal Drug Delivery, in China in 2013. With its long-acting injectable (LAI) platform technologies, including Zpheres® (microspheres), Geleepot® (in-situ gel), and Kriztols® (nanocrystals), Bostal has developed rich clinical stage pipelines of LAIs for GLP-1RAs and Schizophrenia. Lead products in Phase I studies approved by the US FDA include Semaglutide LAI (once monthly); Brexpiprazole LAI (once monthly); and BST-2227 LAI CNS (once bimonthly).
Company HQ City:
Edison
Company HQ State:
NJ
Company HQ Country:
United States
Year Founded:
2004
Lead Product in Development:
Semaglutide LAI (1 M+), Brexpiprazole LAI (1M+), BST-2227 LAI (2M+)
CEO
Ron Liu
Year Founded
2004
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
12
When you expect your next catalyst update?
Successful pharmacokinetic profiles of long acting in humans for at least one of our lead products in the Phase I studies.
What is your next catalyst (value inflection) update?
September 2025
Website
www.bostalpharma.com
Primary Speaker
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}